Pharmadrug Inc.
PHRX
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 23.20K | 15.30K | 271.50K | 463.90K | 75.50K |
| Depreciation & Amortization | 9.20K | 9.20K | 9.30K | 19.30K | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 37.10K | 1.70K | 329.00K | 524.80K | 133.30K |
| Operating Income | -37.10K | -1.70K | -329.00K | -524.80K | -133.30K |
| Income Before Tax | -132.70K | -105.20K | -401.40K | -9.83M | -223.70K |
| Income Tax Expenses | -- | -- | -- | -742.60K | -- |
| Earnings from Continuing Operations | -132.70K | -105.20K | -401.40K | -9.09M | -223.70K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | 44.90K | -- |
| Net Income | -132.70K | -105.20K | -401.40K | -9.04M | -223.70K |
| EBIT | -37.10K | -1.70K | -329.00K | -524.80K | -133.30K |
| EBITDA | -27.90K | 7.50K | -319.70K | -519.90K | -131.10K |
| EPS Basic | 0.00 | 0.00 | 0.00 | -0.12 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | -0.12 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 |
| Average Basic Shares Outstanding | 104.14M | 100.39M | 94.91M | 73.54M | 50.80M |
| Average Diluted Shares Outstanding | 104.14M | 100.39M | 94.91M | 73.54M | 50.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
